Core Viewpoint - Amgen Inc. is experiencing strong performance and positive analyst outlook despite facing some challenges, with a maintained "Buy" rating and an increased price target from Cowen & Co. [1][5] Financial Performance - Amgen's fourth-quarter performance in 2025 exceeded expectations for both revenue and earnings per share, supporting a positive outlook from analysts [2][5] - The stock price is currently $338.59, reflecting a 1.80% decrease or $6.20 drop, with a market capitalization of approximately $182.32 billion [4] Growth Prospects - Key products like Repatha and Uplizna are expected to drive future growth, offsetting losses from Prolia and Xgeva [2][5] - Despite regulatory uncertainties and pipeline attrition, Amgen's long-term prospects remain strong, bolstered by positive data from Repatha and progress with MariTide [3][5] Market Activity - The stock has fluctuated between $338.59 and $349.50 today, with a yearly high of $353.25 and a low of $261.43 [4]

New York, New York--(Newsfile Corp. - February 4, 2026) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, is honored to celebrate the passage of the Mikaela Naylon Give Kids A Chance Act. Mikaela, like so many other children, courageously battled pediatric cancer - specifically Osteosarcoma. Her legacy through this legislation will accelerate critical opportunities for research and therapeutic access for other children an ...

Women We Admire is pleased to announce The Top 50 Women Leaders of Delaware for 2026NEW YORK, Feb. 4, 2026 /PRNewswire-PRWeb/ -- Women We Admire is pleased to announce The Top 50 Women Leaders of Delaware for 2026. Delaware plays an outsized role in the U.S. corporate and financial landscape: more than half of all publicly traded companies and roughly two-thirds of Fortune 500 firms are incorporated there under a legal framework long regarded as the national standard for corporate governance. The state's ec ...

Adjusted EPS was $0.46, up 10% year over year, including a favorable $0.04 impact from foreign exchange. GAAP EPS was $0.24, compared with $0.22 a year earlier.CFO Jim Hipple quantified the impact, saying that excluding the timing effect from those two customers, organic growth would have been 4% for the quarter. Hipple added that the company also benefited from a large OEM commercial supply reagent order that historically landed in fiscal Q3 but shifted into Q2, contributing about 1% to growth in both Prot ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style ...

For the quarter ended December 2025, Techne (TECH) reported revenue of $295.88 million, down 0.4% over the same period last year. EPS came in at $0.46, compared to $0.42 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $292.03 million, representing a surprise of +1.32%. The company delivered an EPS surprise of +8.24%, with the consensus EPS estimate being $0.43.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how ...

The upcoming report from Illumina (ILMN) is expected to reveal quarterly earnings of $1.26 per share, indicating an increase of 46.5% compared to the year-ago period. Analysts forecast revenues of $1.16 billion, representing an increase of 4.6% year over year.The consensus EPS estimate for the quarter has been revised 2.1% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Ahead of a ...

Azenta (NasdaqGS:AZTA) Q1 2026 Earnings call February 04, 2026 08:30 AM ET Speaker6As a reminder, this conference is being recorded Wednesday, February 4, 2026. I will now turn the conference over to Yvonne Perron, Vice President, FP&A, and Investor Relations.Thank you, Operator, and good morning to everyone on the line today. We would like to welcome you to our earnings conference call for the first quarter of fiscal year 2026. Our first quarter earnings press release was issued before the open of the mark ...

MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs today announced the launch of the Defiance Daily Target 2X Long MRNA ETF (MRNX), expanding its lineup of single-stock leveraged ETFs designed for active traders seeking amplified exposure to innovative companies at the forefront of biotechnology and life sciences. MRNX is designed for traders seeking magnified, short-term bullish exposure to Moderna, Inc. (NASDAQ: MRNA), a biotechnology company known for its messenger RNA (mRNA)–based medicines and vacc ...

Core Viewpoint - Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) is currently viewed as a promising investment opportunity, with recent upgrades from analysts indicating increased confidence in the company's prospects [1][2]. Group 1: Analyst Upgrades - Craig-Hallum upgraded Ironwood from Hold to Buy, raising the price target from $3.80 to $5.70 [1]. - Citizens analyst Jason Butler upgraded Ironwood from Market Perform to Outperform, setting a price target of $8, citing restored confidence in the core strength of Linzess [2]. Group 2: Financial Performance and Projections - Butler estimates that Linzess could generate approximately $1.5 billion in brand profit for Ironwood before its loss of exclusivity, which is expected to sufficiently cover the company's existing debt obligations [3]. - The cash flow from Linzess is anticipated to alleviate concerns regarding the company's debt, allowing for a renewed focus on the long-term value of its pipeline asset, apraglutide [2][3]. Group 3: Company Overview - Ironwood Pharmaceuticals is a biotechnology company that develops and commercializes therapies for gastrointestinal and rare diseases both in the US and internationally [4].